NEW YORK, US – [August 05, 2021] – Holmusk, a leading global data science and health technology company building the world’s largest Real-World Evidence (RWE) platform for behavioral health, today announced that three abstracts were accepted and published as part of the Proceedings of the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The meeting brings together over 1200 academic and industry investigators, research pharmacists, and clinicians.
“These high impact ASCP presentations from Holmusk collaborators and investigators illustrate the power of our real-world dataset that we have built and enriched over the last five years,” said Dr. Scott Kollins, Chief Medical Officer at Holmusk. “It is gratifying to see the innovative collaborative work of the Holmusk team and our outside collaborators presented at such a high quality meeting like ASCP.”
The abstracts were selected for poster presentations at ASCP 2021 and have recently been published in the conference’s abstract book. They have each been highlighted below. The complete list of Holmusk’s abstracts and poster presentations can be found at www.ascpp.org/ascp-meetings/ascp-annual-meeting.
Buprenorphine Treatment Retention in Individuals with Opioid Use Disorder (OUD): Insights from Real-World Dataset
• Overview: A retrospective observational study to understand treatment retention among 5000+ OUD patients on Buprenorphine. The team investigated how different factors (e.g., prescription regimens, demographics, clinical variables, care settings at treatment initiation) contribute to treatment retention. The analysis highlights that patient treated in outpatient settings are more likely to remain in treatment than patients seen in inpatient/intensive outpatient care and that an initial dose of 8 mg/day of Buprenorphine is associated with higher retention. Holmusk is currently preparing a manuscript describing study results, which is currently under review of a peer-reviewed journal.
NeuroBlu®: A Longitudinal Real-World Evidence Platform for Behavioral Health Research
• Overview: describes how NeuroBlu® was developed to fuel insight generation in behavioral health, what the platform’s current capabilities are, and how researchers can use the platform for clinical insights on real-world data. For more details of the product, please visit www.neuroblu.ai.
Natural Language Processing-Based Quantification of the Mental State of Psychiatric Patients
• Overview: showcases how psychiatry-specific NLP deep-learning models were developed to transform semi-structured clinician notes into structured data labels which can be leveraged for downstream analysis, how these models perform against other models, and what are some of the potential use cases of NLP data labels (e.g., longitudinal tracking of changes in patient symptoms). See this news story for more details: https://www.prnewswire.com/news-releases/holmusk-announces-new-publication-deep-learning-based-natural-language-processing-models-that-translate-unstructured-psychiatry-notes-into-quantifiable-measures-301228634.html.
Holmusk is on a mission to reinvent behavioral health and transform lives with Real-World Evidence and digital innovation. Headquartered in Singapore and New York, Holmusk generates evidence and builds digital solutions to advance behavioral health research, innovation, and care. NeuroBlu, Holmusk's flagship product, synthesizes Real-World Data (RWD) with seamless analytic tools, enabling users to create actionable insights that drive behavioral health transformation. NeuroBlu is powered by an industry-leading and continually growing behavioral health clinical dataset, with over 20 years of data on 560,000+ patients and 20+ million encounters. Holmusk uses advanced proprietary analytics to enrich the data, with Natural Language Processing and predictive disease models designed specifically for behavioral health. Holmusk augments its data and analytic offerings with powerful digital solutions that enhance patient engagement, support disease self-management, and capture patient-reported outcomes to help guide clinical decisions and analytics. For more information, please visit www.holmusk.com.